124.2  -2.79 (-2.2%)		12-26 16:00
Open: 126.51 High: 126.51 Volume: 401,591		Pre. Close: 126.99 Low: 123.32 Market Cap: 4,244(M)

Short term
Mid term
Targets	6-month :	165.82	1-year :	182.2
Resists	First :	141.97	Second :	156
Pivot price	128.07
Supports	First :	119.29	Second :	99.24
MAs	MA(5) :	127.28	MA(20) :	131.91
	MA(100) :	122.41	MA(250) :	0
MACD	MACD :	-1.3	Signal :	-0.4
%K %D	K(14,3) :	30.1	D(3) :	30.5
RSI	RSI(14): 44
52-week	High :	156	Low :	55

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ TMDX ] has closed above bottom band by 29.6%. Bollinger Bands are 27.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	126.78 - 127.54	127.54 - 128.11
Low:	121.51 - 122.51	122.51 - 123.26
Close:	122.88 - 124.36	124.36 - 125.47

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Thu, 25 Dec 2025
TMDX INVESTORS: Kirby McInerney LLP Reminds TransMedics Group, Inc. Investors of Important Deadline and Encourages Investors to Contact the Firm - TMX Newsfile

Wed, 24 Dec 2025
New TransMedics hires get stock options and units with long vesting - Stock Titan

Wed, 24 Dec 2025
TransMedics Stock: I Estimate An Upside Of Nearly 150% By The End Of 2028 (NASDAQ:TMDX) - Seeking Alpha

Tue, 23 Dec 2025
TransMedics: A Stagnant Monopoly Facing Regulatory Pressure (NASDAQ:TMDX) - Seeking Alpha

Sat, 20 Dec 2025
Zevenbergen Capital Investments LLC Increases Stock Position in TransMedics Group, Inc. $TMDX - MarketBeat

Sat, 13 Dec 2025
Bellevue Group AG Reduces Stake in TransMedics Group, Inc. $TMDX - MarketBeat

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Devices
Shares Out	34 (M)
Shares Float	33 (M)
Held by Insiders	2.9 (%)
Held by Institutions	110.9 (%)
Shares Short	7,720 (K)
Shares Short P.Month	7,540 (K)

EPS	2.53
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	10.39
Profit Margin	16.2 %
Operating Margin	16.2 %
Return on Assets (ttm)	6.9 %
Return on Equity (ttm)	32.4 %
Qtrly Rev. Growth	32.2 %
Gross Profit (p.s.)	9.99
Sales Per Share	16.57
EBITDA (p.s.)	3.52
Qtrly Earnings Growth	450.1 %
Operating Cash Flow	178 (M)
Levered Free Cash Flow	87 (M)

PE Ratio	48.89
PEG Ratio	0
Price to Book value	11.94
Price to Sales	7.49
Price to Cash Flow	23.84

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.